ArticleOncogene2003
LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer.
Article in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 60 citations in OpenAlex.
- Wild-type RAS signaling is an essential therapeutic target inScience signaling · 2025Article
- Single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer tumors.Genome medicine · 2022Article
- Review
- Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA.ACS pharmacology & translational science · 2021Article
- Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival inSmall GTPases · 2021Article
- Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.Science signaling · 2018Article
- Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity.Nature communications · 2017Article
- Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications.Cancer letters · 2017Review
- The role of wild type RAS isoforms in cancer.Seminars in cell & developmental biology · 2016Review
- Genetics and biology of pancreatic ductal adenocarcinoma.Genes & development · 2016Review
- Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.PloS one · 2015Article
- KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2013Article
- Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS.Molecular & cellular proteomics : MCP · 2013Article
- The genetics and biology of KRAS in lung cancer.Chinese journal of cancer · 2013Review
- Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.Oncotarget · 2011Article
- Progressive genomic instability in the FVB/Kras(LA2) mouse model of lung cancer.Molecular cancer research : MCR · 2011Article
- Clinical relevance of KRAS in human cancers.Journal of biomedicine & biotechnology · 2010Review
- Kras regulatory elements and exon 4A determine mutation specificity in lung cancer.Nature genetics · 2008Article
- Tumour maintenance is mediated by eNOS.Nature · 2008Article
- Changes in gene-expression profiles of colon carcinoma cells induced by wild type K-ras2.World journal of gastroenterology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Previous observation has shown that the wild-type Kras2 allele is a suppressor of lung cancer in mice. Here we report that loss of heterozygosity (LOH) of chromosome 12p was detected in approximately 50% of human lung adenocarcinomas and large cell carcinomas, and Kras2 mutations were detected at codon 12 in approximately 40% of adenocarcinomas and large cell carcinomas. Interestingly, all of the lung adenocarcinomas and large cell carcinomas containing a Kras2 mutation exhibited allelic loss of the wild-type Kras2 allele when a correlation between LOH of the region on chromosome 12p and Kras2 mutation was made. These results from human lung cancer tissues provide a strong evidence in support of our previous observation in mouse models that the wild-type Kras2 is a tumor suppressor of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.